[{"orgOrder":0,"company":"Lipidio Pharmaceuticals","sponsor":"Maxim Merchant Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"GDD3898","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipidio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Lipidio Pharmaceuticals \/ Maxim Merchant Capital","highestDevelopmentStatusID":"8","companyTruncated":"Lipidio Pharmaceuticals \/ Maxim Merchant Capital"},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Not Applicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"IBI362","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Fleroxacin","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Not Applicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Green Cross Well-being","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"BST204","moa":"IL-6","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Green Cross Well-being","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Green Cross Well-being \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Green Cross Well-being \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"BI 456906","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Zealand Pharma"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"Pindolol","moa":"Beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"IBI362","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"IBI362","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Not Applicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Not Applicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Dapiglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"XW003","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bimagrumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Series B Financing","leadProduct":"HU6","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Rivus Pharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ RA Capital Management"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glucose","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Aphaia Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"XW003","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bimagrumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Pindolol","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bimagrumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"BI 456906","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Zealand Pharma"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CBL-514","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CBL-514","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"S-pindolol Benzoate","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Oxytocin","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":1.9299999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.9299999999999999,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":1.9299999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.9299999999999999,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VK2735","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CBL-514","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kallyope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"K-757","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Kallyope \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Not Applicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CBL-514","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VK2735","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Veru \/ Raymond James & Associates","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates"},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Veru \/ Raymond James & Associates","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LB54640","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LG Chem","amount2":0.31,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.31,"dosageForm":"","sponsorNew":"LG Chem \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CBL-514","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RGT-075","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Regor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"VK2735","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Danuglipron","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"10xbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Polidocanol","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"10xbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"10xbio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"10xbio \/ Not Applicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Not Applicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Not Applicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dextrose","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Aphaia Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":1,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.90000000000000002,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Goldman Sachs International"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0.90000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.90000000000000002,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Goldman Sachs International"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dextrose","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Aphaia Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"GLY-200","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glyscend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Glyscend Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Glyscend Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Dapiglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Petrelintide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Atlas","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"20-Hydroxyecdysone","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.02,"dosageForm":"","sponsorNew":"Biophytis \/ Atlas","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Atlas"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dextrose","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Aphaia Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"20-Hydroxyecdysone","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Beacon Biosignals","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Beacon Biosignals"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Danuglipron","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"LB54640","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Azelaprag","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nimacimab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CBL-514","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Dapiglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Foralumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Monlunabant","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nimacimab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AZD5004","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eccogene","amount2":2.0099999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.0099999999999998,"dosageForm":"","sponsorNew":"Eccogene \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Eccogene \/ AstraZeneca"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Foralumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Titan Partners Group"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CBL-514","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CBL-514","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nimacimab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Foralumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ ALS Association","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ ALS Association"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nimacimab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Maridebart Cafraglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"IPMC","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Tisolagiline","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Scilex Pharmaceuticals \/ IPMC","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ IPMC"},{"orgOrder":0,"company":"Neurobiogen","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Tisolagiline","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Neurobiogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Neurobiogen \/ Scilex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Neurobiogen \/ Scilex Pharmaceuticals"},{"orgOrder":0,"company":"Vincentage Pharma","sponsor":"Corxel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"VCT220","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Vincentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Vincentage Pharma \/ Corxel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Vincentage Pharma \/ Corxel Pharmaceuticals"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Azelaprag","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Petrelintide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tisolagiline","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tisolagiline","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CBL-514","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Bofanglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Gan & Lee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Metsera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"MET-097i","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Metsera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Inapplicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RGT-075","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Regor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PH284","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Metsera","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.32000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Metsera \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ BofA Securities"},{"orgOrder":0,"company":"Metsera","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.32000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.32000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Metsera \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ BofA Securities"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF alpha","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MC4R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Response Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Response Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
